Inflammation and endometrial cancer: A hypothesis

Cancer Epidemiology Biomarkers and Prevention

Volumn 14, Issue 12, 2005, Pages 2840-2847

  Modugno, Francesmary ^a,b   Ness, Roberta B ^a,b   Chen, Chu ^c,d   Weiss, Noel S ^c  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ESTROGEN; GESTAGEN; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN E2; SEX HORMONE;

ANOVULATION; CANCER GROWTH; CELL DIVISION; CHRONIC INFLAMMATION; DNA REPAIR; ENDOMETRIUM CANCER; ESTROGEN SYNTHESIS; GENE MUTATION; HORMONAL REGULATION; HUMAN; HUMAN CELL; HYPOTHESIS; INFLAMMATION; MALIGNANT TRANSFORMATION; METRORRHAGIA; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; REVIEW;

ANOVULATION; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CELL TRANSFORMATION, NEOPLASTIC; DINOPROSTONE; ENDOMETRIAL NEOPLASMS; FEMALE; HORMONE REPLACEMENT THERAPY; HUMANS; INFLAMMATION; MENSTRUATION DISTURBANCES; POLYCYSTIC OVARY SYNDROME; RISK FACTORS; UNITED STATES;

EID: 30344435634     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-05-0493     Document Type: Review

References (145)

1. Brinton LA, Berman ML, Mortel R, et al. Reproductive, menstrual, and medical risk factors for endometrial cancer: results from a case-control study. Am J Obstet Gynecol 1992;167:1317-25.
2. La Vecchia C, Franceschi S, Decarli A, Gallus G, Tognoni G. Risk factors for endometrial cancer at different ages. J Natl Cancer Inst 1984;73:667-71.
3. Kalandidi A, Tzonou A, Lipworth L, Gamatsi I, Filippa D, Trichopoulos D. A case-control study of endometrial cancer in relation to reproductive, somatometric, and life-style variables. Oncology 1996;53:354-9.
4. Pettersson B, Adami HO, Bergstrom R, Johansson ED. Menstruation span-a time-limited risk factor for endometrial carcinoma. Acta Obstet Gynecol Scand 1986;65:247-55.
5. McPherson CP, Sellers TA, Potter JD, Bostick RM, Folsom AR. Reproductive factors and risk of endometrial cancer. The Iowa Women's Health Study. Am J Epidemiol 1996;143:1195-202.
6. Parazzini F, La Vecchia C, Negri E, Fedele L, Balotta F. Reproductive factors and risk of endometrial cancer. Am J Obstet Gynecol 1991;164:522-7.
7. Javert CT, Renning EL. Endometrial Cancer. Survey of 610 cases at Woman's Hospital (1919-1960). Cancer 1963;16:1057-71.
8. Wynder EL, Escher GC, Mantel N. An epidemiological investigation of cancer of the endometrium. Cancer 1966;19:489-520.
9. Gangemi M, Meneghetti G, Predebon O, Scappatura R, Rocco A. Obesity as a risk factor for endometrial cancer. Clin Exp Obstet Gynecol 1987;14:119-22.
10. Hardiman P, Pillay OC, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma. Lancet 2003;361:1810-2.
11. Elwood JM, Cole P, Rothman KJ, Kaplan SD. Epidemiology of endometrial cancer. J Natl Cancer Inst 1977;59:1055-60.
12. O'Mara BA, Byers T, Schoenfeld E. Diabetes mellitus and cancer risk: a multisite case-control study. J Chronic Dis 1985;38:435-41.
13. Parazzini F, La Vecchia C, Negri E, et al. Diabetes and endometrial cancer: an Italian case-control study. Int J Cancer 1999;81:539-42.
14. Austin H, Austin JM, Jr., Partridge EE, Hatch KD, Shingleton HM. Endometrial cancer, obesity, and body fat distribution. Cancer Res 1991; 51:568-72.
15. Potischman N, Hoover RN, Brinton LA, et al. Case-control study of endogenous steroid hormones and endometrial cancer. J Natl Cancer Inst 1996;88:1127-35.
16. Zeleniuch-Jacquotte A, Akhmedkhanov A, Kato I, et al. Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study. Br J Cancer 2001;84:975-81.
17. Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. N Engl J Med 1975;293:1167-70.
18. Smith DC, Prentice R, Thompson DJ, Herrmann WL. Association of exogenous estrogen and endometrial carcinoma. N Engl J Med 1975;293: 1164-7.
19. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995;85:304-13.
20. Fisher B, Costantino JP, Redmond CK, Fisher ER, Wickerham DL, Cronin WM. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527-37.
21. Killackey MA, Hakes TB, Pierce VK. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 1985;69: 237-8.
22. Kvale G, Heuch I, Ursin G. Reproductive factors and risk of cancer of the uterine corpus: a prospective study. Cancer Res 1988;48:6217-21.
23. Lambe M, Wuu J, Weiderpass E, Hsieh CC. Childbearing at older age and endometrial cancer risk (Sweden). Cancer Causes Control 1999;10:43-9.
24. Kelsey JL, LiVolsi VA, Holford TR, et al. A case-control study of cancer of the endometrium. Am J Epidemiol 1982;116:333-42.
25. Schlesselman JJ. Risk of endometrial cancer in relation to use of combined oral contraceptives. A practitioner's guide to meta-analysis. Hum Reprod 1997;12:1851-63.
26. Weiderpass E, Adami HO, Baron JA, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999;91:1131-7.
27. Key TJ, Pike MC. The dose-effect relationship between "unopposed" oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer 1988;57:205-12.
28. Robinson WS. Hepatitis B virus and hepatocellular carcinoma. In: Parsonnet J, editor. Microbes and malignancy: infection as a cause of human cancers. New York: Oxford University Press; 1999.
29. Lewis JD, Deren JJ, Lichtenstein GR. Cancer risk in patients with inflammatory bowel disease. Gastroenterol Clin North Am 1999;28:459-77.
30. Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW, Jr. Aspirin use and risk of fatal cancer. Cancer Res 1993;53:1322-7.
31. Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994;5:138-46.
32. Paganini-Hill A, Chao A, Ross RK, Henderson BE. Aspirin use and chronic diseases: a cohort study of the elderly. BMJ 1989;299:1247-50.
33. Akhmedkhanov A, Toniolo P, Zeleniuch-Jacquotte A, Kato I, Koenig KL, Shore RE. Aspirin and epithelial ovarian cancer. Prev Med 2001;33: 682-7.
34. Harris RE, Chlebowski RT, Jackson RD, et al. Breast cancer and nonsteroidal anti-inflammatory drugs: prospective results from the Women's Health Initiative. Cancer Res 2003;63:6096-101.
35. O'Byrne KJ, Dalgleish AG. Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer 2001;85:473-83.
36. Balkwill F, Charles KA, Mantovani A. Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 2005;7:211-7.
37. Schwartsburd PM. Age-promoted creation of a pro-cancer microenvironment by inflammation: pathogenesis of discoordinated feedback control. Mech Ageing Dev 2004;125:581-90.
38. Philip M, Rowley DA, Schreiber H. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol 2004;14:433-9.
39. Ristimaki A. Cyclooxygenase 2: from inflammation to carcinogenesis. Novartis Found Symp 2004;256:215-21; discussion 21-6, 59-69.
40. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-7.
41. Hussain SP, Hofseth LJ, Harris CC. Radical causes of cancer. Nat Rev Cancer 2003;3:276-85.
42. Ames BN, Gold LS, Willett WC. The causes and prevention of cancer. Proc Natl Acad Sci U S A 1995;92:5258-65.
43. Morita I. Distinct functions of COX-1 and COX-2. Prostaglandins Other Lipid Mediat 2002;68-9:165-75.
44. Gasparini G, Longo R, Sarmiento R, Morabito A. Inhibitors of cyclooxygenase 2: a new class of anticancer agents? Lancet Oncol 2003;4:605-15.
45. Jacoby RF, Seibert K, Cole CE, Kelloff G, Lubet RA. The cyclooxygenase-2 inhibitor celecoxib is a potent preventive and therapeutic agent in the min mouse model of adenomatous polyposis. Cancer Res 2000; 60:5040-4.
46. Peluffo GD, Stillitani I, Rodriguez VA, Diament MJ, Klein SM. Reduction of tumor progression and paraneoplastic syndrome development in murine lung adenocarcinoma by nonsteroidal antiinflammatory drugs. Int J Cancer 2004;110:825-30.
47. Kumar A, Takada Y, Boriek AM, Aggarwal BB. Nuclear factor-κB: its role in health and disease. J Mol Med 2004;82:434-48.
48. Karin M, Delhase M. The I κ B kinase (IKK) and NF-κB: key elements of proinflammatory signalling. Semin Immunol 2000;12:85-98.
49. Karin M, Ben-Neriah Y. Phosphorylation meets ubiquitination: the control of NF-[κ]B activity. Annu Rev Immunol 2000;18:621-63.
50. Marok R, Winyard PG, Coumbe A, et al. Activation of the transcription factor nuclear factor-κB in human inflamed synovial tissue. Arthritis Rheum 1996;39:583-91,
51. Balkwill F, Coussens LM. Cancer: an inflammatory link. Nature 2004;431: 405-6.
52. Romieu-Mourez R, Landesman-Bollag E, Seldin DC, Traish AM, Mercuric F, Sonenshein GE. Roles of IKK kinases and protein kinase CK2 in activation of nuclear factor-κB in breast cancer. Cancer Res 2001; 61:3810-8.
53. Biswas DK, Shi Q, Baily S, et al. NF-κ B activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci U S A 2004;101:10137-42.
54. Pikarsky E, Porat RM, Stein I, et al. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 2004;431:461-6.
55. Blaustein A. Pathology of the female genital tract. 2nd ed. New York; 1982.
56. Kelly RW, King AE, Critchley HO. Cytokine control in human endometrium. Reproduction 2001;121:3-19.
57. Strauss J, Coutifaris C. The endometrium and myometrium: regulation and dysfunction. In: Yen S, Jaffe R, Barbieri R, editors. Reproductive endocrinology Philadelphia: WB Saunders and Company; 1996.
58. Epifanova OI. Effects of hormones on the cell cycle. In: Baserga R, editor. The cell cycle and cancer. New York: M. Dekker; 1971. p. 145.
59. Srivastava KC. Prostaglandins and platelet function. S Afr J Sci 1978;74:290.
60. Tabibzadeh S. Human endometrium: an active site of cytokine production and action. Endocr Rev 1991;12:272-90.
61. Sugino N, Karube-Harada A, Taketani T, Sakata A, Nakamura Y. Withdrawal of ovarian steroids stimulates prostaglandin F2α production through nuclear factor-κB activation via oxygen radicals in human endometrial stromal cells: potential relevance to menstruation. J Reprod Dev 2004; 50:215-25.
62. Royds JA, Dower SK, Qwarnstrom EE, Lewis CE. Response of tumour cells to hypoxia: role of p53 and NFkB. Mol Pathol 1998;51:55-61.
63. King AE, Critchley HO, Kelly RW. The NF-κB pathway in human endometrium and first trimester decidua. Mol Hum Reprod 2001;7:175-83.
64. Baird DT, Cameron ST, Critchley HO, et al. Prostaglandins and menstruation. Eur J Obstet Gynecol Reprod Biol 1996;70:15-7.
65. Kelly RW. Pregnancy maintenance and parturition: the role of prostaglandin in manipulating the immune and inflammatory response. Endocr Rev 1994;15:684-706.
66. Sales KJ, Jabbour HN. Cyclooxygenase enzymes and prostaglandins in pathology of the endometrium. Reproduction 2003;126:559-67.
67. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001;357:539-45.
68. Daynes RA, Araneo BA, Ershler WB, Maloney C, Li GZ, Ryu SY. Altered regulation of IL-6 production with normal aging. Possible linkage to the age-associated decline in dehydroepiandrosterone and its sulfated derivative. J Immunol 1993;150:5219-30.
69. Wei J, Xu H, Davies JL, Hemmings GP. Increase of plasma IL-6 concentration with age in healthy subjects. Life Sci 1992;51:1953-6.
70. Mohamed-Ali V, Goodrick S, Rawesh A, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-α, in vivo. J Clin Endocrinol Metab 1997;82:4196-200.
71. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-α in human obesity and insulin resistance. J Clin Invest 1995;95:2409-15.
72. Das UN. Is obesity an inflammatory condition? Nutrition 2001;17:953-66.
73. Dandona P, Aljada A, Ghanim H, et al. Increased plasma concentration of macrophage migration inhibitory factor (MIF) and MIF mRNA in mononuclear cells in the obese and the suppressive action of metformin. J Clin Endocrinol Metab 2004;89:5043-7.
74. Visser M, Bouter LM, McQuillan GM, Wener MH, Harris TB. Elevated C-reactive protein levels in overweight and obese adults. JAMA 1999;282:2131-5.
75. Banks RE, Forbes MA, Storr M, et al. The acute phase protein response in patients receiving subcutaneous IL-6. Clin Exp Immunol 1995; 102:217-23.
76. Wisse BE. The inflammatory syndrome: the role of adipose tissue cytokines in metabolic disorders linked to obesity. J Am Soc Nephrol 2004;15:2792-800.
77. Calle EE, Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat Rev Cancer 2004;4:579-91.
78. Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA 2001;286:327-34.
79. Grimble RF. Inflammatory status and insulin resistance. Curr Opin Clin Nutr Metab Care 2002;5:551-9.
80. Gonzalez F, Thusu K, Abdel-Rahman E, Prabhala A, Tomani M, Dandona P. Elevated serum levels of tumor necrosis factor α in normal-weight women with polycystic ovary syndrome. Metabolism 1999;48:437-41.
81. Purohit A, Newman SP, Reed MJ. The role of cytokines in regulating estrogen synthesis: implications for the etiology of breast cancer. Breast Cancer Res 2002;4:65-9.
82. Zhu BT, Conney AH. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 1998;19:1-27.
83. Liehr JG, Ricci MJ, Jefcoate CR, Hannigan EV, Hokanson JA, Zhu BT. 4-Hydroxylation of estradiol by human uterine myometrium and myoma microsomes: implications for the mechanism of uterine tumorigenesis. Proc Natl Acad Sci U S A 1995;92:9220-4.
84. Longcope C, Gorbach S, Goldin B, et al. The effect of a low fat diet on estrogen metabolism. J Clin Endocrinol Metab 1987;64:1246-50.
85. Michnovicz JJ, Hershcopf RJ, Naganuma H, Bradlow HL, Fishman J. Increased 2-hydroxylation of estradiol as a possible mechanism for the anti-esrrogenic effect of cigarette smoking. N Engl J Med 1986;315: 1305-9.
86. Terry PD, Rohan TE, Franceschi S, Weiderpass E. Cigarette smoking and the risk of endometrial cancer. Lancet Oncol 2002;3:470-80.
87. Martucci C, Fishman J. Direction of estradiol metabolism as a control of its hormonal action-uterotrophic activity of estradiol metabolites. Endocrinology 1977;101:1709-15.
88. Purohit A, Singh A, Ghilchik MW, Reed MJ. Inhibition of tumor necrosis factor α-stimulated aromatase activity by microrubule-stabilizing agents, paclitaxel and 2-methoxyestradiol. Biochem Biophys Res Commun 1999;261:214-7.
89. Purohit A, Reed MJ. Regulation of estrogen synthesis in postmenopausal women. Steroids 2002;67:979-83.
90. Finn CA. Implantation, menstruation and inflammation. Biol Rev Camb Philos Soc 1986;61:313-28.
91. Wegmann TG, Lin H, Guilbert L, Mosmann TR. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol Today 1993;14:353-6.
92. Lin H, Mosmann TR, Guilbert L, Tuntipopipat S, Wegmann TG. Synthesis of T helper 2-type cytokines at the maternal-fetal interface. J Immunol 1993;151:4562-73.
93. Kelly RW, King AE, Critchley HO. Inflammatory mediators and endometrial function-focus on the perivascular cell. J Reprod Immunol 2002;57:81-93.
94. Tabibzadeh S, Sun XZ. Cytokine expression in human endometrium throughout the menstrual cycle. Hum Reprod 1992;7:1214-21.
95. Tabibzadeh S. Cytokines and the hypothalamic-pituitary-ovarian- endometrial axis. Hum Reprod 1994;9:947-67.
96. Tazuke SI, Giudice LC. Growth factors and cytokines in endometrium, embryonic development, and maternal: embryonic interactions. Semin Reprod Endocrinol 1996;14:231-45.
97. von Wolff M, Thaler CJ, Zepf C, Becker V, Beier HM, Strowitzki T. Endometrial expression and secretion of interleukin-6 throughout the menstrual cycle. Gynecol Endocrinol 2002;16:121-9.
98. Jacobs AL, Sehgal PB, Julian J, Carson DD. Secretion and hormonal regulation of interleukin-6 production by mouse uterine stromal and polarized epithelial cells cultured in vitro. Endocrinology 1992;131: 1037-46.
99. Laird SM, Li TC, Bolton AE. The production of placental protein 14 and interleukin 6 by human endometrial cells in culture. Hum Reprod 1993;8:793-8.
100. van der Burg B, van der Saag PT. Nuclear factor-κB/steroid hormone receptor interactions as a functional basis of anti-inflammatory action of steroids in reproductive organs. Mol Hum Reprod 1996;2:433-8.
101. Ishihara O, Matsuoka K, Kinoshita K, Sullivan MH, Elder MG. Interleukin-1 β-stimulated PGE2 production from early first trimester human decidual cells is inhibited by dexamethasone and progesterone. Prostaglandins 1995;49:15-26.
102. Vaskivuo TE, Stenback F, Tapanainen JS. Apoptosis and apoptosis-related factors Bcl-2, Bax, tumor necrosis factor-α, and NF-κB in human endometrial hyperplasia and carcinoma. Cancer 2002;95:1463-71.
103. Davies S, Dai D, Feldman I, Pickett G, Leslie KK. Identification of a novel mechanism of NF-κB inactivation by progesterone through progesterone receptors in Hec50co poorly differentiated endometrial cancer cells: induction of A20 and ABIN-2. Gynecol Oncol 2004;94: 463-70.
104. Lydon JP, DeMayo FJ, Funk CR, et al. Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities. Genes Dev 1995; 9:2266-78.
105. Macdiarmid F, Wang D, Duncan LJ, Purohit A, Ghilchick MW, Reed MJ. Stimulation of aromatase activity in breast fibroblasts by tumor necrosis factor α. Mol Cell Endocrinol 1994;106:17-21.
106. Duncan LJ, Coldham NG, Reed MJ. The interaction of cytokines in regulating oestradiol 17β-hydroxysteroid dehydrogenase activity in MCF-7 cells. J Steroid Biochem Mol Biol 1994;49:63-8.
107. Adams EF, Rafferty B, White MC. Interleukin 6 is secreted by breast fibroblasts and stimulates 17β-oestradiol oxidoreductase activity of MCF-7 cells: possible paracrine regulation of breast 17β-oestradiol levels. Int J Cancer 1991;49:118-21.
108. Purohit A, Duncan LJ, Wang DY, Coldham NG, Ghilchick MW, Reed MJ. Paracrine control of oestrogen production in breast cancer. Endocr Relat Cancer 1997;4:323-30.
109. Pallares J, Martinez-Guitarte JL, Dolcet X, et al. Abnormalities in the NF-κB family and related proteins in endometrial carcinoma. J Pathol 2004; 204:569-77.
110. Yoshimatsu K, Golijanin D, Paty PB, et al. Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. Clin Cancer Res 2001;7:3971-6.
111. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ, Jr., Sledge GW, Jr. Constitutive activation of NF-κB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 1997;17: 3629-39.
112. St-Germain ME, Gagnon V, Parent S, Asselin E. Regulation of COX-2 protein expression by Akt in endometrial cancer cells is mediated through NF-κB/IκB pathway. Mol Cancer 2004;3:7.
113. Tamura M, Sebastian S, Yang S, et al. Up-regulation of cyclooxygenase-2 expression and prostaglandin synthesis in endometrial stromal cells by malignant endometrial epithelial cells. A paracrine effect mediated by prostaglandin E2 and nuclear factor-κB. J Biol Chem 2002;277: 26208-16.
114. Ferrandina G, Legge F, Ranelletti FO, et al. Cyclooxygenase-2 expression in endometrial carcinoma: correlation with clinicopathologic parameters and clinical outcome. Cancer 2002;95:801-7.
115. Uotila PJ, Erkkola RU, Klemi PJ. The expression of cyclooxygenase-1 and -2 in proliferative endometrium and endometrial adenocarcinoma. Ann Med 2002;34:428-33.
116. Cao QJ, Einstein MH, Anderson PS, Runowicz CD, Balan R, Jones JG. Expression of COX-2, Ki-67, cyclin D1, and P21 in endometrial endometrioid carcinomas. Int J Gynecol Pathol 2002;21:147-54.
117. Jeon YT, Kang S, Kang DH, et al. Cyclooxygenase-2 and p53 expressions in endometrial cancer. Cancer Epidemiol Biomarkers Prev 2004;13: 1538-42.
118. Punyadeera C, Dunselman G, Marbaix E, et al. Triphasic pattern in the ex vivo response of human proliferative phase endometrium to oestrogens. J Steroid Biochem Mol Biol 2004;92:175-85.
119. Kelly RW, Smith SK. Progesterone and antiprogestins, a comparison of their effect on prostaglandin production by human secretory phase endometrium and decidua. Prostaglandins Leukoc Med 1987;29: 181-6.
120. Abel MH, Baird DT. The effect of 17β-estradiol and progesterone on prostaglandin production by human endometrium maintained in organ culture. Endocrinology 1980;106:1599-606.
121. Critchley HO, Jones RL, Lea RG, et al. Role of inflammatory mediators in human endometrium during progesterone withdrawal and early pregnancy. J Clin Endocrinol Metab 1999;84:240-8.
122. Hsu SC, Long CY, Yang CH, Wu CH, Chen CH, Liu FI. Cyclooxygenase-2 expression in the endometrium at the end of 2 years' continuous combined hormone replacement therapy. Maturitas 2003; 46:295-9.
123. Makarainen L, Ylikorkala O. Primary and myoma-associated menorrhagia: role of prostaglandins and effects of ibuprofen. Br J Obstet Gynaecol 1986; 93:974-8.
124. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-16.
125. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995;83:493-501.
126. DeWitt DL. Prostaglandin endoperoxide synthase: regulation of enzyme expression. Biochim Biophys Acta 1991;1083:121-34.
127. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci U S A 1997;94:3336-40.
128. Arango HA, Icely S, Roberts WS, Cavanagh D, Becker JL. Aspirin effects on endometrial cancer cell growth. Obstet Gynecol 2001;97: 423-7.
129. Gao J, Niwa K, Sun W, et al. Non-steroidal anti-inflammatory drugs inhibit cellular proliferation and upregulate cyclooxygenase-2 protein expression in endometrial cancer cells. Cancer Sci 2004;95:901-7.
130. Li HL, Zhang HW, Chen DD, Zhong L, Ren XD, St-Tu R. JTE-522, a selective COX-2 inhibitor, inhibits cell proliferation and induces apoptosis in RL95-2 cells. Acta Pharmacol Sin 2002;23:631-7.
131. Piazza GA, Alberts DS, Hixson LJ, et al. Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res 1997;57:2909-15.
132. Zhao Y, Agarwal VR, Mendelson CR, Simpson ER. Estrogen biosynthesis proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 1996;137:5739-42.
133. Fang V, Foye WO, Robinson SM, Jenkins HJ. Hypoglycemic activity and chemical structure of the salicylates. J Pharm Sci 1968;57:2111-6.
134. Graef I, Gibbons DM. Salicylates and carbohydrate metabolism. Diabetes 1960;9:416-8.
135. Powell ED, Field RA. Studies on salicylates and complement in diabetes. Diabetes 1966;15:730-3.
136. McRae JR, Chen M, Robertson RP. Improvement of defective insulin responses to glucose, arginine, and β-adrenergic stimulation in diabetics by sodium salicylate. Adv Prostaglandin Thromboxane Res 1980;8: 1287-9.
137. Baron SH. Salicylates as hypoglycemic agents. Diabetes Care 1982;5: 64-71.
138. Hundal RS, Petersen KF, Mayerson AB, et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 2002;109:1321-6.
139. Amann R, Peskar BA. Anti-inflammatory effects of aspirin and sodium salicylate. Eur J Pharmacol 2002;447:1-9.
140. Colantoni A, de Maria N, Caraceni P, Bernardi M, Floyd RA, Van Thiel DH. Prevention of reoxygenation injury by sodium salicylate in isolated-perfused rat liver. Free Radic Biol Med 1998;25:87-94.
141. van Jaarsveld H, Kuyl JM, van Zyl GF, Barnard HC. Salicylate in the perfusate during ischemia/reperfusion prevented mitochondrial injury. Res Commun Mol Pathol Pharmacol 1994;86:287-95.
142. Shackelford RE, Alford PB, Xue Y, Thai SF, Adams DO, Pizzo S. Aspirin inhibits tumor necrosis factorα gene expression in murine tissue macrophages. Mol Pharmacol 1997;52:421-9.
143. Kroeger KM, Steer JH, Joyce DA, Abraham LJ. Effects of stimulus and cell type on the expression of the -308 tumour necrosis factor promoter polymorphism. Cytokine 2000;12:110-9.
144. Terry CF, Loukaci V, Green FR. Cooperative influence of genetic polymorphisms on interleukin 6 transcriptional regulation. J Biol Chem 2000;275:18138-44.
145. Akhmedkhanov A, Zeleniuch-Jacquotte A, Toniolo P. Role of exogenous and endogenous hormones in endometrial cancer: review of the evidence and research perspectives. Ann N Y Acad Sci 2001;943:296-315.